GP
BIVV

GLG Partners’s Bioverativ Inc. Common Stock BIVV Stock Holding History

GLG Partners’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$4K Buy
+71
New +$3.88K ﹤0.01% 471

Other funds holding BIVV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JIM
Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

GLG Partners's BIVV Position: Q4 2017 in Review

GLG Partners opened a new position in Bioverativ Inc. Common Stock (BIVV) in Q4 2017: 71 shares worth $4K. The stake represents ﹤0.01% of the portfolio and ranks #471 among its holdings.

459 funds tracked by Wall St. Rank hold BIVV as of Q4 2017.

  • GLG Partners held 71 shares of Bioverativ Inc. Common Stock worth $4K as of Q4 2017.
  • Bioverativ Inc. Common Stock was a new GLG Partners position in Q4 2017.
  • Bioverativ Inc. Common Stock made up ﹤0.01% of GLG Partners's portfolio in Q4 2017, its #471 holding.
  • 459 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q4 2017.

Based on GLG Partners's 13F filing for Q4 2017, filed 14 Feb 2018.